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Abstract 
Despite the recent development of various radiolabelled RGD peptides for imaging the v3 
integrin receptor, relatively little attention has been focused on the ability of these radiotracers to 
monitor changes in tumour vascularity following treatment with anti-tumour therapies. Here we 
describe the favourable in vivo kinetics and tumour targeting properties of several novel radio-
labeled RGD containing peptides that have the ability to monitor tumour vascularity non-invasively 
in a variety of preclinical tumor models. These tracers may reveal important information when 
assessing the impact of anti-tumour therapies, in particular those that predominantly target tu-
mour blood vessels. Consequently, these radiolabelled RGD targeting agents represent a useful 
approach to quantify tumor vasculature, and when used alone or in combination with additional 
functional  imaging  modalities,  should  enhance  our  mechanistic  understanding  of  how  novel 
therapeutic strategies impact upon tumors. 
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INTRODUCTION 
A  number  of  novel  therapeutic  strategies  are 
currently  being  examined  clinically  which  aim  to 
modify  tumour  vasculature  function,  growth  and 
survival [1]. These include inhibition of vascular en-
dothelial growth factor-A (VEGF) signaling [1] (a key 
regulator of tumour angiogenesis, vascular permea-
bility and neovascular survival), use of vascular dis-
rupting  agents  (VDAs)  such  as  the  tubu-
lin-depolymerising  agent  combretastatin  A-4  [2],  or 
examination of low dose cytotoxic chemotherapy [3]. 
To monitor the effect of VEGF signaling inhibitors or 
VDAs, Magnetic Resonance Imaging (MRI) or Com-
puterised  Tomography  (CT),  and  in  particular  Dy-
namic  Contrast  Enhanced  MRI  (DCE-MRI)  and  CT 
(DCE-CT)  have  been  employed  successfully  to  pro-
vide  evidence  of  an  effect  on  tumour  blood  flow, 
blood  volume  and  permeability  [4-5].  However,  an 
obvious current limitation to being able to understand 
the full activity of approaches that target the tumour 
vasculature,  is  the  lack  of  a  non-invasive  imaging 
method to quantify changes in tumour vascularity in 
cancer patients [6]. This may become of greater im-
portance as alternative (i.e. non-VEGF / VDA) thera-
pies are progressed clinically [1], since these may have 
more subtle and less predictable acute effects on tu-
mour haemodynamics.  
Integrins are composed of a family of heterodi-
meric  glycoproteins  involved  in  cell-cell  and 
cell-matrix interactions  [7]. They consist of   and  
subunits that form noncovalent   heterodimers [8] 
and  are the major receptors by which cells attach to 
the  extracellular  matrix  (ECM).  The  v3  integrin, Theranostics 2011, 1 
 
http://www.thno.org 
150 
which  is  preferentially  expressed  on  proliferating 
endothelial cells associated with neovascularisation in 
both malignant tumours and normal tissue, but not in 
quiescent blood vessels [9-10], has been identified as a 
target  for  imaging  neovasculature.  Others  have 
shown  previously  [11-13]  that  RGD  peptides  can 
serve as a targeting biomolecule to carry a range of 
radionuclides (e.g.,  18F,  99mTc and  64Cu) to the  v3 
integrin.  Thus,  targeting  the  v3  integrin  receptor 
with  [18F]fluciclatide  (formerly  known  as 
[18F]AH111585)  could  provide  us  with  a  tool  to  ex-
amine  the  effect  of  vascular  modulation  therapies 
directly,  without  having  to  rely  on  consequential 
changes  in  blood  perfusion  and  permeability.  This 
may be particularly pertinent to examining therapies 
that specifically target the tumour vasculature, given 
that  their  activity  may  not  lead  to  a  substantial  tu-
mour  mass/volume  reduction  soon  after  therapy 
[14-15].  Hence  conventional  measurements  of  re-
sponse may be insensitive or markedly delayed even 
when there is a significant therapeutic effect. Direct 
clinical  imaging  of  tumour  neovasculature,  could 
therefore  afford  the  opportunity  to  optimise 
dose-selection  during  early  examination  of  a  novel 
anti-vascular therapy. 
Previously, quantification of tumour vasculature 
has been assessed in surgical specimens or preclinical 
samples  using  immunohistochemical  methods. 
However, not only is there potential variability in the 
measurement  of  MVD  [15],  dependent  upon  the 
marker  (e.g.  CD31,  CD105)  or  endpoint  used  (e.g. 
Chalkey  Counts,  whole  tumour  image  analysis, 
“hot-spot” analysis), but  such assays are not practical 
in clinical trials. The ethical and physical limitations of 
serial invasive procedures and the inherent anatomic 
and physiologic heterogeneity of tumours is likely to 
necessitate multiple samples being taken at any given 
time-point  [16].  Clearly  a  non-invasive  method  for 
assessing  tumour  vascularity  could  obviate  these 
technical challenges. 
[18F]fluciclatide is a novel cyclic RGD-based ra-
dioligand for  v3 /v5, , an analogue of a peptide 
pharmacophore isolated from a phage display library 
[17].  The  original  peptide  sequence  (RGD-4C)  was 
optimised extensively to improve in vivo stability and 
increase plasma half-life [18] whilst maintaining high 
affinity  for  v3 /v5:  the  observed  Ki  for  the  cold 
compound (AH111585) was calculated to be 10.2 nM 
in  competition  with  radioactive  125I-Echistatin,  an 
RGD-containing peptide isolated from snake venom. 
In addition, the fact that [18F]fluciclatide is able 
to target neovasculature via the  v3/v5 receptors 
expressed  on  endothelial  cells  is  supported  by  the 
work of Pasqualini et al., who demonstrated that tu-
mour vessels were the structural elements most tar-
geted by the RGD sequence [19].  
USE OF RGD-BASED RADIOLIGANDS 
FOR THERAPY MONITORING 
Although several groups have developed radio-
labelled RGD compounds which have shown promise 
in terms of tumour uptake and tumour to background 
ratios  [20-22],  relatively  little  attention  has  been  fo-
cused on the ability of these radiotracers to monitor 
the  response  of  tumors  to  therapies  that  target  the 
vasculature, the most likely clinical use of these im-
aging agents. One exception is the work by Jung et al. 
[23] who have demonstrated that paclitaxel therapy 
(an  anti-microtubule  agent  commonly  used  in  the 
treatment  of  breast  and  NSCLC  [24])  resulted  in  a 
decreased  LLC  uptake  of  a  99mTc-labelled  glucosa-
mino RGD containing peptide. The authors stated that 
these data support the use of the radiolabelled RGD 
peptide  for  monitoring  response  to  anti-angiogenic 
therapy.  
We  have  also  demonstrated  the  utility  of 
[18F]fluciclatide in determining changes in the level of 
tumor vascularity following treatment with the same 
chemotherapeutic  agent,  paclitaxel  [25].    However, 
one  important  point  to  note  is  that  in  our  study, 
paclitaxel  was  used  at  lower  doses  to  that  used  by 
Jung et al.; animals were dosed at 5 and 10 mg/kg. At 
these  low  doses,  paclitaxel  is  reported  to  cause  an 
anti-angiogenic  effect  without  significant  tumour 
shrinkage [26].   
In  order  to  acquire  comparison  data  to 
[18F]fluciclatide,  we  co-injected  [14C]-FDG  with 
[18F]fluciclatide  post  paclitaxel  therapy  in  order  to 
generate data with an imaging agent (when 18F radi-
olabelled)  that  is  used  extensively  in  the  clinic  for 
tumour  imaging  [27].  18Ffluciclatide  tumour  uptake 
was more sensitive to paclitaxel therapy, since a re-
duction in uptake was seen while [14C]-FDG uptake 
remained  unchanged  (Fig.  1).    The  reduction  in 
[18F]fluciclatide uptake was matched by a decrease in 
the tumour h-MVD: with low dose paclitaxel, a 20% 
decrease in MVD was detected when compared to a 
separate group of vehicle control treated LLC tumors.  
This demonstrates that [18F]fluciclatide is able to de-
tect vascular changes that occur through the use of 
paclitaxel.  It is postulated that the slight increase in 
uptake with [14C]-FDG in the paclitaxel treated ani-
mals reflected the inflammatory flare typically seen 
with  [18F]-FDG  after  therapy  [28],  but  this  was  not 
significant.  
Following  on  from  the  promising  results  seen 
with  paclitaxel  and  [18F]fluciclatide,  we  were  inter-
ested  to  understand  the  impact  of  more  novel  an-Theranostics 2011, 1 
 
http://www.thno.org 
151 
ti-angiogenic  therapies  on  [18F]fluciclatide  uptake 
preclinically.    Initially  we  assessed  the  impact  of 
ZD4190, a small molecular VEGFR-2 tyrosine kinase 
inhibitor [29].  ZD4190 was administered orally (100 
mg/kg)  to  mice  bearing  Calu-6  tumors  after  tumor 
establishment on 3 occasions following a baseline PET 
scan with a follow up PET scan on day 3.  
 
 
Figure 1. Inhibition of [
18F]fluciclatide uptake by low dose 
paclitaxel (5 and 10 mg/kg) therapy in the mouse Lewis Lung 
tumour model (120 minutes p.i. of [
18F]fluciclatide, day 15 
post LLC cell inoculation).  At the same paclitaxel dose 
level, no effect was observed on [
14C]-FDG uptake. Values 
are expressed in %id/g and presented as Mean (SD) of 2 
experiments (n=4). *P<0.05 compared with corresponding 
control group. 
 
As  can  be  seen  (Fig.  2),  the  uptake  of 
[18F]fluciclatide in Calu-6 tumors was reduced signif-
icantly with 3 doses of ZD4190, with an average re-
duction  in  the  percentage  injected  dose  per  gram 
(%ID/g) across the 10 animals examined of 31.8% ± 
4.6% (based on the imaging region-of-interest (ROI) 
data).  Skeletal muscle was used as a reference tissue 
for ROI analysis, and the data demonstrate that mus-
cle uptake was maintained before and after therapy, 
indicating that the tumor decrease seen with ZD4190 
therapy was specific.  Comparison with the vehicle 
control  animals  demonstrates  that  over  the  same 
3-day  dosing  period,  the  Calu-6  tumor  uptake  of 
18Ffluciclatide  increased  from  the  pre  to  the  post 
treatment image, with an average increase of 26.9% ± 
9.4%.  Statistical  analysis  of  the  treated  and  control 
groups demonstrated a clear difference at the P<0.01 
level (determined via t test).  
Figure 3 shows representative fused small ani-
mal  PET  and  micro-CT  images  for  ZD4190-treated 
and vehicle control animals. The before and after im-
ages  show  decreased  [18F]fluciclatide  uptake  (with 
ZD4190  therapy)  and  an  increased  [18F]fluciclatide 
uptake (with vehicle control) before and after therapy.  
 
Figure 2. Summarized data demonstrating the percentage 
change in uptake of [
18F]fluciclatide in Calu-6 tumors, pre 
and post treatment with 3 doses ZD4190 (100 mg/kg) or 
vehicle  control.  Data  presented  for  individual  animals. 
*P<0.01 compared to vehicle control group. 
 
Figure 3.    Representative co-registered microPET and 
microCT images demonstrating [
18F]fluciclatide uptake at 
120 min in the Calu-6 tumour model pre (a) and post (b) Theranostics 2011, 1 
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administration of 3 doses of vehicle control or pre (c) and 
post (d) 3 doses of ZD4190 (100 mg/kg). Contrast is clearly 
seen in the Calu-6 tumours located on the left shoulder 
region  in  both  the  ZD4190  treated  and  vehicle  control 
animals. The only additional higher activity concentration 
was found in the bladder. In addition, 
22Na fiducial markers 
can be seen located on the base of the imaging bed (used for 
PET/CT co-registration).  ROI analysis for tumour uptake 
pre ZD4190 therapy was 1.7 %Id/g decreasing to 1.1 %Id/g 
post ZD4190 therapy. Muscle uptake was maintained at 0.5 
%Id/g in pre and post ZD4190 therapy images. For animals 
treated with vehicle control alone, ROI analysis for tumour 
uptake pre-vehicle control was 2.1 %Id/g increasing to 2.5 
%Id/g post-therapy. Muscle uptake was maintained at 0.3 
%Id/g in pre and post therapy images. 
 
 
We have also carried out additional preclinical 
studies using sunitinib (Sutent, Pfizer, Inc.), an oral, 
small molecule tyrosine kinase inhibitor with nano-
molar affinity against the VEGFR and PDGFR tyro-
sine  kinases  [30].    U87MG  bearing  animals  were 
dosed  with  sunitinib  or  vehicle  alone  using  a 
five-day-on/two-day-off  treatment  cycle  previously 
described [31].  In a similar way to that described for 
ZD4190, sunitinib was able to significantly reduce the 
uptake of [18F]fluciclatide compared to vehicle control 
treated U87MG xenograft tumors from day 2 onward 
post therapy initiation.   
The  Weber  group  has  also  recently  published 
data assessing whether their radiolabelled RGD agent 
([64Cu]DOTA-cyclo-(RGDfK)) can be used for moni-
toring response to the Src family kinase inhibitor da-
satinib [32].  Using U87MG xenograft tumors dosed 
daily over 3 days with 72 or 95 mg/kg dasatinib or 
vehicle  they  found  that  the  uptake  of 
[64Cu]DOTA-cyclo-(RGDfK)  was  significantly  re-
duced  in the 95 mg/kg dose group by 59% compared 
to control animals.  The group also reported that in 
contrast  to  the  decrease  seen  with 
[64Cu]DOTA-cyclo-(RGDfK)  in  dasatinib  treated  tu-
mours, 18F-FDG uptake showed no significant reduc-
tion,  which  matches  the  data  we  generated  using 
[14C]FDG with paclitaxel therapy.  
In conclusion, the data emerging from our own 
studies  and  those  of  Jung  et  al.  and  Dumont  et  al. 
suggest that radiolabelled RGD agents with favorable 
biodistribution properties do allow the non-invasive 
assessment  of  tumour  vascularity  and  response  to 
treatments that have an effect on the tumour vascular 
compartment. Additionally preliminary clinical stud-
ies  with  our  tracer,  [18F]fluciclatide  have  already 
proven that this radioligand can successfully image 
metastatic breast cancer lesions [33]: 7 patients with a 
total of 18 tumors detectable by computer tomogra-
phy (CT) were imaged with [18F]fluciclatide PET, and 
all tumors were visible.  Similar work has also been 
published using other radiolabelled RGD agents, in, 
for example, malignant melanoma [34]. 
Consequently,  these  radiolabelled  RGD  target-
ing  agent  represents  a  useful  approach  to  quantify 
tumour vasculature, and when used alone or in com-
bination with additional functional imaging modali-
ties, should enhance our mechanistic understanding 
of how novel therapeutic strategies impact upon tu-
mors. 
ACKNOWLEDGMENTS 
We would like to thank Pfizer and AstraZeneca 
for their kind contribution by supplying the sunitinib 
and ZD4190 compounds respectively for use in these 
studies. 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
1.  Folkman  J.  Angiogenesis:  an  organizing  principle  for  drug 
discovery? Nat Rev Drug Discov. 2007;6:273-86. 
2.  Hinnen  P,  Eskens  FA.  Vascular  disrupting  agents  in  clinical 
development. Br J Cancer. 2007;96:1159-65. 
3.  Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel 
RS.  Anti-angiogenic  treatment  of  breast  cancer  using 
metronomic low-dose chemotherapy. Breast. 2005;14:466-79. 
4.  Bradley DP, Tessier JL, Checkley D, Kuribayashi H, Waterton 
JC,  Kendrew  J,  et  al.  Effects  of  AZD2171  and  vandetanib 
(ZD6474, Zactima) on haemodynamic variables in an SW620 
human colon tumour model: an investigation using dynamic 
contrast-enhanced  MRI  and  the  rapid  clearance  blood  pool 
contrast  agent,  P792  (gadomelitol).  NMR  Biomed. 
2008;21:42-52. 
5.  Daldrup-Link  HE,  Simon  GH,  Brasch  RC.  Imaging of tumor 
angiogenesis:  current  approaches  and  future  prospects.  Curr 
Pharm Des. 2006;12:2661-72. 
6.  McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg 
WD, Folkman J, et al. Report from the society for biological 
therapy and vascular biology faculty of the NCI workshop on 
angiogenesis monitoring. J Immunother. 2004;27:161-75. 
7.  Horton  MA.  The  αvβ3  integrin  "vitronectin  receptor".  Int  J 
Biochem Cell Biol. 1997;29:721-5. 
8.  Hynes RO. Integrins: versatility, modulation, and signaling in 
cell adhesion. Cell. 1992;69:11-25. 
9.  Eliceiri BP, Cheresh DA. The role of alphav integrins during 
angiogenesis: insights into potential mechanisms of action and 
clinical development. J Clin Invest. 1999;103:1227-30. 
10.  Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, 
Klier  G,  et  al.  Integrin  αvβ3  antagonists  promote  tumor 
regression by inducing apoptosis of angiogenic blood vessels. 
Cell. 1994;79:1157-64. 
11.  Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik 
P, et al. Patterns of αvβ3 expression in primary and metastatic 
human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl 
Med. 2008;49:255-9. Theranostics 2011, 1 
 
http://www.thno.org 
153 
12.  Chen  X,  Tohme  M,  Park  R,  Hou  Y,  Bading  JR,  Conti  PS. 
Micro-PET  imaging  of  αvβ3-integrin  expression  with 
18F-labeled dimeric RGD peptide. Mol Imaging. 2004;3:96-104. 
13.  Haubner  RH,  Wester  HJ,  Weber  WA,  Schwaiger  M. 
Radiotracer-based strategies to image angiogenesis. Q J Nucl 
Med. 2003;47:189-99. 
14.  Hahnfeldt  P,  Panigrahy  D,  Folkman  J,  Hlatky  L.  Tumor 
development under angiogenic signaling: a dynamical theory 
of  tumor  growth,  treatment  response,  and  postvascular 
dormancy. Cancer Res. 1999;59:4770-5. 
15.  Hlatky  L,  Hahnfeldt  P,  Folkman  J.  Clinical  application  of 
antiangiogenic therapy: microvessel density, what it does and 
doesn't tell us. J Natl Cancer Inst. 2002;94:883-93. 
16.  Gerber HP, Ferrara N. Pharmacology and pharmacodynamics 
of  bevacizumab  as  monotherapy  or  in  combination  with 
cytotoxic  therapy  in  preclinical  studies.  Cancer  Res. 
2005;65:671-80. 
17.  Pasqualini R, Koivunen E, Ruoslahti E. A peptide isolated from 
phage display libraries is a structural and functional mimic of 
an RGD-binding site on integrins. J Cell Biol. 1995;130:1189-96. 
18.  Indrevoll B, Kindberg GM, Solbakken M, Bjurgert E, Johansen 
JH,  Karlsen  H,  et  al.  NC-100717:  a  versatile  RGD  peptide 
scaffold  for  angiogenesis  imaging.  Bioorg  Med  Chem  Lett. 
2006;16:6190-3. 
19.  Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as 
receptors  for  tumor  targeting  by  circulating  ligands.  Nat 
Biotechnol. 1997;15:542-6. 
20.  Liu S, Hsieh WY, Jiang Y, Kim YS, Sreerama SG, Chen X, et al. 
Evaluation  of  a  99mTc-labeled  cyclic  RGD  tetramer  for 
noninvasive  imaging  integrin  αvβ3-positive  breast  cancer. 
Bioconjug Chem. 2007;18:438-46. 
21.  Haubner R. Alphavbeta3-integrin imaging: a new approach to 
characterise  angiogenesis?  Eur  J  Nucl  Med  Mol  Imaging. 
2006;33 (Suppl 1):54-63. 
22.  Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik 
P, et al. Patterns of αvβ3 Expression in Primary and Metastatic 
Human  Breast  Cancer  as  Shown  by  18F-Galacto-RGD  PET.  J 
Nucl Med. 2008;49:255-9. 
23.  Jung  KH,  Lee  KH,  Paik  JY,  Ko  BH,  Bae  JS,  Lee  BC,  et  al. 
Favorable  biokinetic  and  tumor-targeting  properties  of 
99mTc-labeled  glucosamino  RGD  and  effect  of  paclitaxel 
therapy. J Nucl Med. 2006;47:2000-7. 
24.  Horwitz  SB.  Taxol  (paclitaxel):  mechanisms  of  action.  Ann 
Oncol. 1994;5 (Suppl 6):S3-6. 
25.  Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, 
Wedge  SR.  Use  of  a  novel  Arg-Gly-Asp  radioligand, 
18F-AH111585, to determine changes in tumor vascularity after 
antitumor therapy. J Nucl Med. 2009;50:116-22. 
26.  Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel 
(Taxol): an inhibitor of angiogenesis in a highly vascularized 
transgenic  breast  cancer.  Cancer  Biother  Radiopharm. 
1999;14:31-6. 
27.  Juweid  ME.  Utility  of  positron  emission  tomography  (PET) 
scanning  in  managing  patients  with  Hodgkin  lymphoma. 
Hematology Am Soc Hematol Educ Program. 2006;:259-65. 
28.  Mortimer  JE,  Dehdashti  F,  Siegel  BA,  Trinkaus  K, 
Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of 
hormone  responsiveness  in  advanced  breast  cancer.  J  Clin 
Oncol. 2001;19:2797-803. 
29.  Wedge  SR,  Ogilvie  DJ,  Dukes  M,  Kendrew  J,  Curwen  JO, 
Hennequin  LF,  et  al.  ZD4190:  an  orally  active  inhibitor  of 
vascular  endothelial  growth  factor  signaling  with 
broad-spectrum antitumor efficacy. Cancer Res. 2000;60:970-5. 
30.  Westermark B, Heldin CH, Nister M. Platelet-derived growth 
factor in human glioma. Glia. 1995;15:257-63. 
31.  de  Bouard  S,  Herlin  P,  Christensen  JG,  Lemoisson  E, 
Gauduchon  P,  Raymond  E,  et  al.  Antiangiogenic  and 
anti-invasive  effects  of  sunitinib  on  experimental  human 
glioblastoma. Neuro Oncol. 2007;9:412-23. 
32.  Dumont  RA,  Hildebrandt  I,  Su  H,  Haubner  R,  Reischl  G, 
Czernin JG, et al. Noninvasive imaging of αvβ3 function as a 
predictor of the antimigratory and antiproliferative effects of 
dasatinib. Cancer Res. 2009;69:3173-9. 
33.  Kenny  LM,  Coombes  CR,  Oulie  I,  Contractor  K,  Miller  M, 
Spinks T, et al. The RGD radioligand [18F]AH111585: A novel 
probe for imaging αvβ3 and αvβ5 receptor levels by positron 
emission  tomography  in  breast  cancer  patients.  J Nucl  Med. 
2008;49:879-86. 
34.  Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia 
M,  et  al.  Noninvasive  visualization  of  the  activated  αvβ3 
integrin in cancer patients by positron emission tomography 
and [18F]Galacto-RGD. PLoS Med. 2005;2:e70. 